Safety reporting in developing country vaccine clinical trials-A systematic review

Vaccine

Volumn 30, Issue 22, 2012, Pages 3255-3265

  Muehlhans, Susann ^a   Richard, Georgina ^b   Ali, Mohammad ^c   Codarini, Gabriela ^d   Elemuwa, Chris ^e   Khamesipour, Ali ^f   Maurer, Wolfgang ^g   Mworozi, Edison ^h   Kochhar, Sonali ⁱ   Rundblad, Gabriella ^j   Vuitton, Dominique ^k   Rath, Barbara ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c International Vaccine Institute   (South Korea)

^d Stamboulian Vaccination Center   (Argentina)

^e Federal Ministry of Health   (Nigeria)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g Medical University of Vienna   (Austria)

^h MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

ⁱ Institute for One World Health   (India)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k UNIVERSITÉ DE FRANCHE COMTÉ   (France)

more..

Author keywords

AEFI; Developing countries; Randomized clinical trials; Safety reporting; Vaccines

Indexed keywords

BCG VACCINE; CHOLERA VACCINE; DENGUE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SCHISTOSOMA VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ADVERSE OUTCOME; APPETITE DISORDER; DEVELOPING COUNTRY; DIARRHEA; DISEASE SEVERITY; EMBASE; ERYTHEMA; FEVER; FOLLOW UP; GROUPS BY AGE; HEADACHE; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; INTUSSUSCEPTION; IRRITABILITY; MEDLINE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SWELLING; SYSTEMATIC REVIEW; VACCINATION; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DEVELOPING COUNTRIES; DRUG TOXICITY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES;

EID: 84859834317     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.059     Document Type: Review

References (98)

1. Gidudu J., Sack D.A., Pina M., Hudson M.J., Kohl K.S., Bishop P., et al. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29:1053-1071.
2. Gidudu J., Kohl K.S., Halperin S., Hammer S.J., Heath P.T., Hennig R., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008, 26:6800-6813.
3. Michael Marcy S., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22:551-556.
4. Kohl K.S., Walop W., Gidudu J., Ball L., Halperin S., Hammer S.J., et al. Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5839-5857.
5. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22:259-267.
6. Kohl K.S., Walop W., Gidudu J., Ball L., Halperin S., Hammer S.J., et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007, 25:5858-5874.
7. Bonhoeffer J., Menkes J., Gold M.S., de Souza-Brito G., Fisher M.C., Halsey N., et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22:557-562.
8. Bines J.E., Kohl K.S., Forster J., Zanardi L.R., Davis R.L., Hansen J., et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22:569-574.
9. Moorthy V., Reed Z., Smith P.G. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007, 25:5115-5123.
10. Bonhoeffer J., Vermeer P., Halperin S., Kempe A., Music S., Shindman J., et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22:586-591.
11. Clemens J., Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat Med 2005, 11:S12-S15.
12. Law B. New developments and capabilities globally. Vaccine Safety Evaluation - Post Marketing Surveillance Conference 2007 April 10-11, 2007; 13, AEFI, accessed November 30, 2011. http://www.hhs.gov/nvpo/documents/14Law.ppt.
13. Poland G.A. Methodologic reporting requirements for clinical trials: advancing the science today and tomorrow. Vaccine 2011, 29:5087-5089.
14. Maurer W. Vaccine nomenclature: the three-letter code, OMCL Vaccine Nomenclature Drafting Group. Vaccine 2000, 18:1539-1542.
15. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
16. UN. World Economic and Social Survey 2006. English ed. New York, NY: United Nations, Department of Economic and Social Affairs, Development Policy and Analysis Division; 2006.
17. Cochrane Collaboration. Glossary of Terms in The Cochrane Collaboration. 2005 May [cited 14.02.2012]; available from: http://www.cochrane.org/sites/default/files/uploads/glossary.pdf.
18. Price D., Jefferson T., Demicheli V. Methodological issues arising from systematic reviews of the evidence of safety of vaccines. Vaccine 2004, 22:2080-2084.
19. Wong L.P. Knowledge and attitudes about HPV infection, HPV vaccination, and cervical cancer among rural southeast Asian women. Int J Behav Med 2011, 18:105-111.
20. Yeboah-Antwi K., Pilingana P., Macleod W.B., Semrau K., Siazeele K., Kalesha P., et al. Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial. PLoS Med 2010, 7:e1000340.
21. Asante K.P., Abdulla S., Agnandji S., Lyimo J., Vekemans J., Soulanoudjingar S., et al. Safety and efficacy of the RTS, S/AS01(E) candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:741-749.
22. Yang J., Acosta C.J., Si G., Zeng J., Li C.Y., Liang D.B., et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in Southeast China: a cluster-randomized trial. BMC Public Health 2005, 5:49.
23. Cherian T., Thomas N., Raghupathy P., Durot I., Dutta A. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age. Indian Pediatr 2002, 39:427-436.
24. Panchanathan V., Kumar S., Yeap W., Devi S., Ismail R., Sarijan S., et al. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits. Bull World Health Organ 2001, 79:811-817.
25. Punjabi N.H., Richie E.L., Simanjuntak C.H., Harjanto S.J., Wangsasaputra F., Arjoso S., et al. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. Vaccine 2006, 24:1776-1785.
26. Sirima S.B., Nebie I., Ouedraogo A., Tiono A.B., Konate A.T., Gansane A., et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007, 25:2723-2732.
27. Thera M.A., Doumbo O.K., Coulibaly D., Diallo D.A., Sagara I., Dicko A., et al. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial. PLoS Clin Trials 2006, 1:e34.
28. Imoukhuede E.B., Berthoud T., Milligan P., Bojang K., Ismaili J., Keating S., et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 2006, 24:6526-6533.
29. Stoute J.A., Gombe J., Withers M.R., Siangla J., McKinney D., Onyango M., et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007, 25:176-184.
30. Herrera S., Bonelo A., Perlaza B.L., Fernandez O.L., Victoria L., Lenis A.M., et al. Safety and elicitation of humoral and cellular responses in Colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 2005, 73:3-9.
31. Saha A., Chowdhury M.I., Khanam F., Bhuiyan M.S., Chowdhury F., Khan A.I., et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 2011, 29:8285-8292.
32. Macete E., Aponte J.J., Guinovart C., Sacarlal J., Ofori-Anyinam O., Mandomando I., et al. Safety and immunogenicity of the RTS, S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 2007, 12:37-46.
33. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Kone A.K., Guindo A.B., et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PloS ONE 2010, 5:e9041.
34. Dicko D., Sagara A., Ellis I., Miura R.D., Guindo K., Kamate O.B., et al. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PloS ONE 2008, 3:e1563.
35. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 25(374):301-314.
36. Steele A.D., Madhi S.A., Louw C.E., Bos P., Tumbo J.M., Werner C.M., et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J 2011, 30:125-130.
37. Kim K.H., Lee H., Chung E.H., Kang J.H., Kim J.H., Kim J.S., et al. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. J Korean Med Sci 2008, 23:929-936.
38. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 16(364):2293-2304.
39. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365:1863-1875.
40. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007, 25:2120-2127.
41. Mahalanabis D., Ramamurthy T., Nair G.B., Ghosh A., Shaikh S., Sen B., et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009, 30(27):4850-4856.
42. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 21(376):615-623.
43. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 21(376):606-614.
44. Guandalini S. Treatment of acute diarrhea in the new millennium. J Pediatr Gastroenterol Nutr 2000, 30:486.
45. Lanata C.F., Midthun K., Black R.E., Butron B., Huapaya A., Penny M.E., et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996, 174:268-275.
46. Ruiz-Palacios G.M., Perez-Schael I., Raul Velazquez F., Abate H., Breuer T., Costa Clemens S., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
47. CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Definition and Application of Terms for Vaccine Pharmacovigilance. 2012 [cited 15.02.2012]; available from: http://whqlibdoc.who.int/publications/2012/9789290360834_eng.pdf.
48. European Medicines Agency. Guideline on Clinical Evaluation of new Vaccines. October 2006 18, EMEA/CHMP/VWP/164653/2005 2006.
49. Gold M.S., Gidudu J., Erlewyn-Lajeunesse M., Law B. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010, 28:4487-4498.
50. Enría D.A., Feuillade M.R. Análisis de la utilidad de la vacuna Candid 1 en la prevención de la fiebre hemorrágica argentina en niños. Revista con revisión por pares de la Organización Panamericana de la Salud 2006, 18:100-106.
51. Ryan E.T., Calderwood S.B. Cholera vaccines. J Travel Med 2001, 8:82-91.
52. Widman D.G., Frolov I., Mason P.W. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Adv Virus Res 2008, 72:77-126.
53. Mulligan M.J. Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions. Curr Infect Dis Rep 2009, 11:399-406.
54. Alter G., Ananworanich J., Pantophlet R., Rybicki E.P., Buonaguro L. Report on the AIDS vaccine 2008 conference. Hum Vaccin 2009, 5:119-125.
55. Hotez P.J., Bethony J.M., Diemert D.J., Pearson M., Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010, 8:814-826.
56. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
57. Graves P., Gelband H. Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database Syst Rev 2006, CD006198.
58. Todd C.W. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am J Trop Med Hyg 2002, 66:348-358.
59. Ibanga H.B., Brookes R.H., Hill P.C., Owiafe P.K., Fletcher H.A., Lienhardt C., et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 2006, 6:522-528.
60. Acosta C.J., Galindo C.M., Ali M., Elyazeed R.A., Ochiai R.L., Danovaro-Holliday M.C., et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop Med Int Health 2005, 10:1219.
61. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002, 51:1-11.
62. Natunen K., Lehtinen J., Namujju P., Sellors J., Lehtinen M. Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol 2011, 2011. Article ID 675858, 10 pp.
63. Meissner H.C., Strebel P.M., Orenstein W.A. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004, 114:1065-1069.
64. Munyoro M.N., Kufa E., Biellik R., Pazvakavambwa I.E., Cairns K.L. Impact of nationwide measles vaccination campaign among children aged 9 months to 14 years, Zimbabwe, 1998-2001. J Infect Dis 2003, 187(May (Suppl. 1)):S91-S96.
65. Okoko B.J., Idoko O.T., Adegbola R.A. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine 2009, 27:2023-2029.
66. LoBue A.D., Thompson J.M., Lindesmith L., Johnston R.E., Baric R.S. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 2009, 83:3212-3227.
67. Levine O.S., O'Brien K.L., Knoll M., Adegbola R.A., Black S., Cherian T., et al. Pneumococcal vaccination in developing countries. Lancet 2006, 367:1880-1882.
68. Abzug M.J., Pelton S.I., Song L.Y., Fenton T., Levin M.J., Nachman S.A., et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006, 25:920-929.
69. Katz S.L. Polio - new challenges in 2006. J Clin Virol 2006, 36(July):163-165.
70. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine(WC 3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
71. Ali M., Canh G.D., Clemens J.D., Park J.K., von Seidlein L., Minh T.T., et al. The use of a computerized database to monitor vaccine safety in Viet Nam. Bull World Health Organ 2005, 83:604-610.
72. Massad E., Azevedo-Neto R.S., Burattini M.N., Zanetta D.M.T., Coutinho F.A., Yang H.M. Assessing the efficacy of a mixed vaccination strategy against rubella in Sao Paulo, Brazil. Int J Epidemiol 1995, 24:842-850.
73. Khan M.I., Ochiai R.L., Hamza H.B., Sahito S.M., Habib M.A., Soofi S.B., et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials 2006, 7(1):17.
74. Sharifi I., FeKri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351(9115):1540-1543.
75. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999, 17:466-472.
76. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
77. Sur D., Kanungo S., Sah B., Manna B., Ali M., Paisley A.M., et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 2011, 5:e1289.
78. Ahmed T., Svennerholm A.M., Al Tarique A., Sultana G.N., Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine 2009, 27:1433-1439.
79. Bresee J.S., El Arifeen S., Azim T., Chakraborty J., Mounts A.W., Podder G., et al. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh. Pediatr Infect Dis J 2001, 20:1136-1143.
80. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PloS ONE 2008, 3:e2323.
81. Migasena S., Pitisuttitham P., Prayurahong B., Suntharasamai P., Supanaranond W., Desakorn V., et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 1989, 57:3261-3264.
82. Dagan R., Melamed R., Zamir O., Leroy O. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997, 16:1053-1059.
83. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 26(344):1263-1269.
84. Neuzil K.M., Canh do G., Thiem V.D., Janmohamed A., Huong V.M., Tang Y., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011, 305:1424-1431.
85. Lang J., Hoa D.Q., Gioi N.V., Vien N.C., Nguyen C.V., Rouyrre N., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999, 93:208-213.
86. Anh D.D., Canh do G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007, 25:1149-1155.
87. Salinas B., Schael I.P., Linhares A.C., Palacios R., Guerrero M.L., Yarzabal J.P., et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005, 24:807-816.
88. Christie C.D., Duncan N.D., Thame K.A., Onorato M.T., Smith H.D., Malcolm L.G., et al. Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization. Pediatrics 2010, 126:e1499-e1506.
89. Linhares A.C., Gabbay Y.B., Mascarenhas J.D., de Freitas R.B., Oliveira C.S., Bellesi N., et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 1996, 74:491-500.
90. Taylor D.N., Tacket C.O., Losonsky G., Castro O., Gutierrez J., Meza R., et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997, 65:3852-3856.
91. Mulholland K., Hilton S., Adegbola R., Usen S., Oparaugo A., Omosigho C., et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997, 349:1191-1197.
92. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
93. Cutts F.T., Zaman S.M.A., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146.
94. Obaro S.K., Enwere G.C., Deloria M., Jaffar S., Goldblatt D., Brainsby K., et al. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 2002, 21:940-947.
95. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171-1176.
96. Steele A.D., De Vos B., Tumbo J., Reynders J., Scholtz F., Bos P., et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2010, 28:6542-6548.
97. Matjila M.J., Phohu T.C., Banzhoff A., Viviani S., Hoosen A.A., Bianchini M., et al. Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines. S Afr Med J 2004, 94:43-46.
98. World Health Organization. WHO regional offices. 2011 [cited 02.02.2012]; available from: http://www.who.int/about/regions/en/index.html.